IPN-01194
- Generic Name
- IPN-01194
Ipsen Secures €500 Million Inaugural Rated Public Bond Following Investment Grade Ratings
• Ipsen has successfully completed its first Rated Public Bond of €500 million with a 3.875% coupon maturing in March 2032, following Investment Grade ratings from S&P (BBB-) and Moody's (Baa3).
• The transaction was heavily oversubscribed by institutional investors, demonstrating market confidence in Ipsen's financial strategy and long-term growth prospects.
• This bond issuance is part of Ipsen's broader refinancing plan, which recently included the renewal of a €1.5 billion Revolving Credit Facility, significantly extending the company's debt maturity profile.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath